FridaySep 29, 2017 12:52 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event

Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins Growing portfolio of intellectual property includes 19 patents filed across 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is…

Continue Reading

WednesdaySep 27, 2017 3:19 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies

Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has…

Continue Reading

MondaySep 25, 2017 3:46 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Attains $43M in Capital, Plans Significant Production Capacity Increase

Aaron Keay, CEO, says plans set for greater production capacity and strategy for global distribution in emerging markets Expansion of ABcann’s Vanluven facility underway, along with construction of the company’s 150,000 sq. ft. Kimmett facility Napanee, Ontario-based firm uses proprietary plant-growing technology and is pursuing opportunities in Australia and Germany ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) achieved working capital of $43 million from multiple financings, including private placements and strategic partnerships, during the six months ended June 30, 2017, it announced on August 29 (http://cnw.fm/1BXpf). ABcann manufactures and distributes medical cannabis under a license issued by Health Canada to…

Continue Reading

MondaySep 25, 2017 1:45 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Technology Targets Many Massive Markets

Technology that improves bio-absorption and bio-availability Bioactive compound delivery system with application across a range of drugs Revenue streams from out-licensing The word in culinary circles is that where there is fat, there is flavor. That’s because fats (there are several different kinds) have a matchless ability to absorb and preserve flavors. Fats belong to a class of compounds called lipids, which the human digestive system absorbs remarkably efficiently. This characteristic makes them ideal for pairing with hard to digest remedials and tonics. Taking a leaf, perhaps, from haute cuisine, this is exactly what Lexaria Bioscience Corp. (CSE: LXX) (OTCQB:…

Continue Reading

WednesdaySep 20, 2017 3:25 pm

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) is “One to Watch”

Amid a continued boom in the growing cannabis sector, Canada is moving rapidly toward legalization as the U.S. continues to foot drag at the federal level, leading many sector analysts to conclude that it’s the Canadian companies who might benefit the most as an underlying shift toward medical and recreational use continues. Out of a tiny handful of just 58 Health Canada-licensed producers, vertically integrated Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) stands out as a one of the fastest growing cultivators and pharma developers, having also obtained authorization to produce cannabis oils. While sales of dried marijuana intended for smoking…

Continue Reading

WednesdaySep 20, 2017 10:07 am

The Green Organic Dutchman Rides on Quality Medical Cannabis, Private Placement and Strong Leadership

The Green Organic Dutchman (“TGOD”), a 100-percent owned subsidiary of The Green Organic Dutchman Holdings Ltd., produces high-quality medical marijuana. Its organic medical cannabis is farm grown and pesticide-free. There are many factors in favor of the company. The demand in a legal national market, consumer preference for organic foods and products of all kinds and a recent $20 million private placement are all positive signs. Also, TGOD is among a select group of companies licensed to cultivate medical cannabis by Health Canada under the Access to Cannabis for Medical Purposes Regulations. Those interested in investing should contact TGOD directly…

Continue Reading

TuesdaySep 19, 2017 4:10 pm

The Green Organic Dutchman Holdings Ltd. Announces $20M Private Placement as Company Moves toward Expansion

Company has, to date, raised $41.5 million and has more than 2,400 shareholders Has one of the largest licensed land parcels in Canada, situated on 100 acres Offers organically grown, pesticide-free medical marijuana under Canada’s ACMPR The Green Organic Dutchman Holdings Ltd. (“TGOD”), a Canadian company engaged in producing farm-grown, high-quality organic medical cannabis using craft growing, all natural, organic principles, announced on September 11 (http://cnw.fm/jHbs0) that it has entered into an agreement with a syndicate led by PI Financial Corp. to complete a private placement offering of units. The syndicate will offer, on a commercially reasonable effort basis, 4,242,500…

Continue Reading

TuesdaySep 19, 2017 3:33 pm

At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles

Producer of consistent, standardized medicinal cannabis Menu of cannabis strains with varying CBD:THC ratios ABcann’s CBD-Med is one of Canada's highest-CBD products In an interview with Cantech Letter (http://cnw.fm/g2AtB), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis…

Continue Reading

ThursdaySep 14, 2017 2:31 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology

Proprietary biosynthesis process to produce cannabinoids Provisional patent application filed Cost-effective methodology to produce trace cannabinoids If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind. Known worldwide for his investing prowess, Warren Buffett has said, “I don't want a business that's easy for competitors. I want a business with a moat around it with a very valuable castle in the middle” (http://cnw.fm/ehB50). Naturally, the Sage of Omaha was…

Continue Reading

WednesdaySep 13, 2017 3:58 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract,…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977